Results 11 to 20 of about 17,959 (132)
Ibrain, 2023 Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989.
Bin-Can Tang, Ya-Ting Wang
exaly +2 more sources
MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients [PDF]
HemaSphereAdministration of memantine, an antagonist of the N‐methyl‐ d‐aspartate receptor, prevents Ca2+ overload and dehydration of red blood cells (RBCs) in patients with sickle cell disease (SCD).
Ariel Koren +7 more
doaj +2 more sources
Combined Inhibition of TRPM4/NMDA Receptor Complex and Extrasynaptic NMDA Receptors Is Candidate Therapeutic Target for Suppression of Epileptic Seizures and Improvement of Cognitive Impairments [PDF]
Pharmacology Research & PerspectivesCognitive impairments are important therapeutic targets in epilepsy medication; however, effective pharmacological treatments for epilepsy patients with comorbid cognitive impairment have not been established. Effects of chronic administration of MK‐801 (
Motohiro Okada +3 more
doaj +2 more sources
International Journal of Electrochemical Science, 2009 Memantine (MEM) is one of the first novel class medications for treatment of Alzheimer's disease. In this study a potentiometric liquid membrane sensor is used for simple and fast determination of Memantine in pharmaceutical formulation and urine ...
Mohammad Reza Ganjali +2 more
exaly +3 more sources
Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study [PDF]
Annals of Clinical and Translational NeurologyObjective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited.
Peiyu Wang +7 more
doaj +2 more sources
Update on the use of memantine in Alzheimer’s disease
Neuropsychiatric Disease and Treatment, 2009 Robert J van MarumGeriatric Department, University Medical Center Utrecht, Utrecht, The NetherlandsAbstract: Memantine is a low to moderate affinity N-methyl-D-aspartate receptor (NMDAR) antagonist.
Robert J van Marum
exaly +2 more sources
Pharmaceuticals, 2022 Glutamate is an excitatory neurotransmitter in the nervous system. Excessive glutamate transmission can lead to increased calcium ion expression, related to increased neurotoxicity.
Radoslav Chayrov +7 more
doaj +1 more source
The Highs and Lows of Memantine—An Autophagy and Mitophagy Inducing Agent That Protects Mitochondria
Cells, 2023 Memantine is an FDA-approved, non-competitive NMDA-receptor antagonist that has been shown to have mitochondrial protective effects, improve cell viability and enhance clearance of Aβ42 peptide.
Sholto de Wet +7 more
doaj +1 more source
BMC Neurology, 2022 Background Mild cognitive impairment in Parkinson’s disease (PD-MCI) is associated with an increased risk of cognitive decline. PD-MCI is characterized by impairments in executive function and visuospatial recognition.
Shoji Kawashima +2 more
doaj +1 more source
Neuromodulation: Technology at the Neural Interface, EarlyView., 2021 Abstract Objectives Obsessive–compulsive disorder (OCD) is a psychiatric disorder with alterations of cortico‐striato‐thalamo‐cortical loops and impaired performance monitoring. Electrophysiological markers such as conflict‐related medial frontal theta (MFT) and error‐related negativity (ERN) may be altered by clinically effective deep brain ...
Elena Sildatke +9 more
wiley +1 more source